Chinese consumers, just like Westerners, are lining up for DNA tests. But unlike their American and European counterparts, the Chinese appear to have far fewer qualms about privacy and sharing their data.
Do exercise-tracking apps and gadgets like Fitbit make us healthier? Or do they just create a high-tech, data-centric illusion of control over our weight, sleep and general well-being?
Some of the health information we generate from apps, DNA kits and fitness trackers can be sold to brokers who trade it like a commodity. How worried should we be?
On our latest episode of Prognosis, reporter Kristen V. Brown sets out to peddle her own DNA to the highest bidder.
Scientists are learning they greatly overestimated chances of developing deadly cancers in patients with no family history of disease.
A century-old quest for family records to unite relatives in heaven has transformed the church into a global leader in genealogy technology.
In the wake of privacy concerns, a group of Berlin-based feminist coders announced they were doing something different with their app.
In the genealogy business, finding out your dad isn’t your dad has a technical term: It’s called an non-paternity event, or an NPE.
Some patients can't wait for pharmaceutical companies to develop drugs. They're pushing the drug industry to make the cures they and their loved ones need. But what's good for patients is also good for pharma's profits, creating a web of murky incentives that makes the issue of high drug costs all the more difficult to parse. In episode 8 of the Prognosis podcast, Bloomberg's Rebecca Spalding talks to these professional patients about their relationships to the big companies whose therapies they need.
Should a patient dying of a disease with no proven cure have the right to try whatever experimental drug they want? A controversial new law signed by President Trump this year says that they should, bypassing the FDA. In episode seven, Bloomberg's Michelle Fay Cortez explores what the new Right To Try law means for desperate patients who want access to experimental treatments. It isn't as simple as it sounds.
Bloomberg's Rebecca Spalding tells the surprising journey of one life-saving drug, from discovery to market. It's a story about a Nobel Prize winner, cutting edge genetic research, billions of pharmaceutical dollars, and of all things, a worm. What does it tell us about health care in America?
Researchers and pharmaceutical companies have poured time and money into developing an effective drug to combat obesity. But time and again, the drugs have failed to deliver.
In episode three of Prognosis, Kristen V. Brown and Sarah McBride take a trip to Burning Man.
Today we'll take you on a tour of a biohacker's DNA experiment to change how frogs—and possibly people—grow muscles. It's an experiment which he insists anyone can try at home. He'll even sell you a kit—frogs included—to do it
DIYers used a security flaw to bypass the $8.3 billion insulin delivery business with a cobbled-together artificial pancreas